Related Experiment Video
Updated: Jul 4, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Allosteric Hsp70 Modulator YM-1 Induces Degradation of BRD4
Yugo Mishima1, Shusuke Tomoshige1, Shinichi Sato1,2
1Graduate School of Life Sciences, Tohoku University.
Abstract:
YM-1, an allosteric modulator of heat-shock 70 kDa protein (Hsp70), inhibits cancer cell growth, but the mechanism is not yet fully understood. Here, we show that YM-1 induces the degradation of bromodomain containing 4 (BRD4), which mediates oncogene expression. Overall, our results indicate that YM-1 promotes the binding of HSP70 to BRD4, and this in turn promotes the ubiquitination of BRD4 by C-terminus of Hsc70-interacting protein (CHIP), an E3 ubiquitin ligase working in concert with Hsp70, leading to proteasomal degradation of BRD4. This YM-1-induced decrease of BRD4 would contribute at least in part to the inhibition of cancer cell growth.
Insights
YM-1, a heat-shock 70 kDa protein (Hsp70) modulator, triggers cancer cell death by promoting the degradation of bromodomain containing 4 (BRD4). This mechanism involves Hsp70, CHIP, and BRD4 ubiquitination, leading to reduced oncogene expression.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Heat-shock 70 kDa protein (Hsp70) is a crucial molecular chaperone implicated in cancer.
- YM-1 is an allosteric modulator of Hsp70 with known anticancer properties, but its precise mechanism of action remains unclear.
- Bromodomain containing 4 (BRD4) is a key regulator of oncogene expression and a validated therapeutic target in various cancers.
Purpose of the Study:
- To elucidate the molecular mechanism by which YM-1 inhibits cancer cell growth.
- To investigate the role of Hsp70 and its interacting partners in YM-1-mediated anti-cancer effects.
- To determine if YM-1 affects the stability or expression of BRD4.
Main Methods:
- Cell-based assays to assess cancer cell viability and proliferation.
- Western blotting and immunoprecipitation to detect protein-protein interactions and degradation.
- Ubiquitination assays to identify the role of E3 ligases.
- Quantitative real-time PCR to measure gene expression levels.
Main Results:
- YM-1 treatment led to the degradation of BRD4 in cancer cells.
- YM-1 enhanced the binding between Hsp70 and BRD4.
- Hsp70-mediated recruitment of C-terminus of Hsc70-interacting protein (CHIP) resulted in BRD4 ubiquitination and subsequent proteasomal degradation.
- The decrease in BRD4 levels correlated with reduced oncogene expression and inhibited cancer cell growth.
Conclusions:
- YM-1 inhibits cancer cell growth by inducing the proteasomal degradation of BRD4.
- The mechanism involves the formation of an Hsp70-BRD4 complex, facilitating BRD4 ubiquitination by CHIP.
- Targeting the Hsp70-BRD4-CHIP axis represents a potential therapeutic strategy for cancers driven by BRD4.
More Related Videos
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Export of Misfolded Proteins out of the ER
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
GPCR Desensitization

